United States· US:62064-122_c04624be-0e28-4902-954c-730ccdbfd162
TROGARZO
A ibalizumab product containing ibalizumab, registered in United States by Theratechnologies Inc.. The same ATC class is registered in 4 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ibalizumab is registered in 4 of 19 countries.
Countries holding a registration under ATC J05AX23 (ibalizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Ibalizumab · ATC J05AX23
4 / 19 countries
- Belgiumprice
- Finlandprice
- Spainprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IBALIZUMAB
- Manufacturer
- Theratechnologies Inc.
- Country
- United States (US)
- ATC code
- J05AX23
- ATC class
- Ibalizumab
- Defined daily dose
- 57 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1162064-122-02
- ndc1162064122022 VIAL, SINGLE-USE in 1 CARTON (62064-122-02) / 1.33 mL in 1 VIAL, SINGLE-USE (62064-122-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ibalizumab in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db9a5cfd-fbe6-46ce-8254-4428465093b4 GET /v1/drugs/db9a5cfd-fbe6-46ce-8254-4428465093b4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "150",
"substance": "IBALIZUMAB",
"productndc": "62064-122",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761065",
"marketing_category": "BLA"
}See everything about ibalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.